InterMune Halts Phase III Actimmune Lung Disease Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will focus on pirfenidone for idiopathic pulmonary fibrosis after Actimmune failed to show a statistically significant treatment effect over placebo.